Metformin for the Treatment of Hidradenitis Suppurativa (HS)

Last updated: October 9, 2023
Sponsor: K.R. van Straalen
Overall Status: Completed

Phase

3

Condition

Acne Inversa

Rosacea

Hidradenitis Suppurativa

Treatment

Metformin

Clinical Study ID

NCT04649502
EMCD20022
  • Ages > 18
  • All Genders

Study Summary

A randomized controlled trial investigating the metformin is the treatment for hidradenitis suppurativa. Metformin combined with doxycycline will be compared to the standard treatment of doxycycline monotherapy for HS severity and the effect on the pre-diabetic condition.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥18 years at baseline
  • A diagnosis of HS for at least 1 year prior to baseline
  • mild to moderately active disease defined by a HS Physician Global Assessment (HS-PGA)score of 2-3 and the Refined Hurley classification of mild to moderate at baseline
  • Indication for systemic therapy; i.e. uncontrolled disease under conventional topicaltherapy.
  • Able and willing to give written informed consent and to comply with the studyrequirements

Exclusion

Exclusion Criteria:

  • Pregnant and lactating women
  • Concomitant diabetes mellitus
  • Use of antibiotics within 14 days prior to baseline
  • Use of immunosuppressing/modulating therapies within 28 days prior to baseline
  • A known allergy to metformin or doxycycline or any of the ingredients metformin ordoxycycline

Study Design

Total Participants: 62
Treatment Group(s): 1
Primary Treatment: Metformin
Phase: 3
Study Start date:
January 25, 2021
Estimated Completion Date:
August 23, 2023

Connect with a study center

  • Erasmus MC

    Rotterdam,
    Netherlands

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.